Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of the ...
This score calculates overall vulnerability severity from 0 to 10 and is based on the Common Vulnerability Scoring System (CVSS). Attack Vector: This metric reflects the context by which vulnerability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback